133 related articles for article (PubMed ID: 22692919)
1. Oncolytic virotherapy for human bone and soft tissue sarcomas using live attenuated poliovirus.
Atsumi S; Matsumine A; Toyoda H; Niimi R; Iino T; Nakamura T; Matsubara T; Asanuma K; Komada Y; Uchida A; Sudo A
Int J Oncol; 2012 Sep; 41(3):893-902. PubMed ID: 22692919
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic treatment and cure of neuroblastoma by a novel attenuated poliovirus in a novel poliovirus-susceptible animal model.
Toyoda H; Yin J; Mueller S; Wimmer E; Cello J
Cancer Res; 2007 Mar; 67(6):2857-64. PubMed ID: 17363609
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of telomerase-specific oncolytic virotherapy for human bone and soft tissue sarcomas.
Sasaki T; Tazawa H; Hasei J; Kunisada T; Yoshida A; Hashimoto Y; Yano S; Yoshida R; Uno F; Kagawa S; Morimoto Y; Urata Y; Ozaki T; Fujiwara T
Clin Cancer Res; 2011 Apr; 17(7):1828-38. PubMed ID: 21325287
[TBL] [Abstract][Full Text] [Related]
4. Experimental treatment of human neuroblastoma using live-attenuated poliovirus.
Toyoda H; Ido M; Hayashi T; Gabazza EC; Suzuki K; Kisenge RR; Kang J; Hori H; Komada Y
Int J Oncol; 2004 Jan; 24(1):49-58. PubMed ID: 14654940
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic poliovirus therapy and immunization with poliovirus-infected cell lysate induces potent antitumor immunity against neuroblastoma in vivo.
Toyoda H; Wimmer E; Cello J
Int J Oncol; 2011 Jan; 38(1):81-7. PubMed ID: 21109928
[TBL] [Abstract][Full Text] [Related]
6. Analysis of poliovirus receptor, CD155 expression in different human colorectal cancer cell lines: Implications for poliovirus virotherapy.
Zhand S; Hosseini SM; Tabarraei A; Moradi A; Saeidi M
J Cancer Res Ther; 2019; 15(1):61-67. PubMed ID: 30880756
[TBL] [Abstract][Full Text] [Related]
7. Poliovirus receptor CD155-targeted oncolysis of glioma.
Merrill MK; Bernhardt G; Sampson JH; Wikstrand CJ; Bigner DD; Gromeier M
Neuro Oncol; 2004 Jul; 6(3):208-17. PubMed ID: 15279713
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic vesicular stomatitis virus administered by isolated limb perfusion suppresses osteosarcoma growth.
Kubo T; Shimose S; Matsuo T; Fujimori J; Sakaguchi T; Yamaki M; Shinozaki K; Woo SL; Ochi M
J Orthop Res; 2011 May; 29(5):795-800. PubMed ID: 21437961
[TBL] [Abstract][Full Text] [Related]
9. Direct and bystander killing of sarcomas by novel cytosine deaminase fusion gene.
Ramnaraine M; Pan W; Goblirsch M; Lynch C; Lewis V; Orchard P; Mantyh P; Clohisy DR
Cancer Res; 2003 Oct; 63(20):6847-54. PubMed ID: 14583482
[TBL] [Abstract][Full Text] [Related]
10. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme.
Liu C; Sarkaria JN; Petell CA; Paraskevakou G; Zollman PJ; Schroeder M; Carlson B; Decker PA; Wu W; James CD; Russell SJ; Galanis E
Clin Cancer Res; 2007 Dec; 13(23):7155-65. PubMed ID: 18056196
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of polyuridylic acid in human soft tissue and bone sarcomas.
Adepoju LJ; Geiger JD
J Surg Res; 2010 Nov; 164(1):e107-14. PubMed ID: 20828720
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic Semliki forest virus vector as a novel candidate against unresectable osteosarcoma.
Ketola A; Hinkkanen A; Yongabi F; Furu P; Määttä AM; Liimatainen T; Pirinen R; Björn M; Hakkarainen T; Mäkinen K; Wahlfors J; Pellinen R
Cancer Res; 2008 Oct; 68(20):8342-50. PubMed ID: 18922906
[TBL] [Abstract][Full Text] [Related]
13. Progress of oncolytic viruses in sarcomas.
Lettieri CK; Hingorani P; Kolb EA
Expert Rev Anticancer Ther; 2012 Feb; 12(2):229-42. PubMed ID: 22316371
[TBL] [Abstract][Full Text] [Related]
14. Growth phenotypes and biosafety profiles in poliovirus-receptor transgenic mice of recombinant oncolytic polio/human rhinoviruses.
Cello J; Toyoda H; Dejesus N; Dobrikova EY; Gromeier M; Wimmer E
J Med Virol; 2008 Feb; 80(2):352-9. PubMed ID: 18098139
[TBL] [Abstract][Full Text] [Related]
15. Enhanced therapeutic efficacy of oncolytic herpes vector G207 against human non-small cell lung cancer--expression of an RNA-binding protein, Musashi1, as a marker for the tailored gene therapy.
Kanai R; Eguchi K; Takahashi M; Goldman S; Okano H; Kawase T; Yazaki T
J Gene Med; 2006 Nov; 8(11):1329-40. PubMed ID: 16955534
[TBL] [Abstract][Full Text] [Related]
16. Canine Adipose-Derived Mesenchymal Stem Cells (cAdMSCs) as a "Trojan Horse" in Vaccinia Virus Mediated Oncolytic Therapy against Canine Soft Tissue Sarcomas.
Petrov I; Gentschev I; Vyalkova A; Elashry MI; Klymiuk MC; Arnhold S; Szalay AA
Viruses; 2020 Jul; 12(7):. PubMed ID: 32664672
[TBL] [Abstract][Full Text] [Related]
17. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
Aghi M; Rabkin SD; Martuza RL
Cancer Res; 2007 Jan; 67(2):440-4. PubMed ID: 17234749
[TBL] [Abstract][Full Text] [Related]
18. Effective oncolytic vaccinia therapy for human sarcomas.
He S; Li P; Chen CH; Bakst RL; Chernichenko N; Yu YA; Chen N; Szalay AA; Yu Z; Fong Y; Wong RJ
J Surg Res; 2012 Jun; 175(2):e53-60. PubMed ID: 22341347
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic herpes simplex virus treatment of metastatic breast cancer.
Wang J; Hu P; Zeng M; Rabkin SD; Liu R
Int J Oncol; 2012 Mar; 40(3):757-63. PubMed ID: 22108767
[TBL] [Abstract][Full Text] [Related]
20. Tumor suppression by apoptotic and anti-angiogenic effects of mortalin-targeting adeno-oncolytic virus.
Yoo JY; Ryu J; Gao R; Yaguchi T; Kaul SC; Wadhwa R; Yun CO
J Gene Med; 2010 Jul; 12(7):586-95. PubMed ID: 20603860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
